Bank of New York Mellon’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-513
| Closed | -$4.41K | – | 4307 |
|
|
2024
Q1 | $4.41K | Hold |
513
| – | – | ﹤0.01% | 4140 |
|
|
2023
Q4 | $1.8K | Hold |
513
| – | – | ﹤0.01% | 4305 |
|
|
2023
Q3 | $1.83K | Hold |
513
| – | – | ﹤0.01% | 4338 |
|
|
2023
Q2 | $2.98K | Sell |
513
-2,817
| -85% | -$51.5K | ﹤0.01% | 4373 |
|
|
2023
Q1 | $126K | Hold |
3,330
| – | – | ﹤0.01% | 4034 |
|
|
2022
Q4 | $99.2K | Sell |
3,330
-22
| -0.7% | -$665 | ﹤0.01% | 4119 |
|
|
2022
Q3 | $112K | Hold |
3,352
| – | – | ﹤0.01% | 4176 |
|
|
2022
Q2 | $134K | Sell |
3,352
-3,761
| -53% | -$146K | ﹤0.01% | 4169 |
|
|
2022
Q1 | $374K | Buy |
7,113
+2,859
| +67% | +$144K | ﹤0.01% | 3884 |
|
|
2021
Q4 | $235K | Hold |
4,254
| – | – | ﹤0.01% | 4206 |
|
|
2021
Q3 | $330K | Hold |
4,254
| – | – | ﹤0.01% | 4005 |
|
|
2021
Q2 | $553K | Hold |
4,254
| – | – | ﹤0.01% | 3723 |
|
|
2021
Q1 | $700K | Buy |
4,254
+1,133
| +36% | +$218K | ﹤0.01% | 3518 |
|
|
2020
Q4 | $730K | Buy |
+3,121
| New | +$434K | ﹤0.01% | 3434 |
|
|
2018
Q4 | – | Sell |
-132
| Closed | -$54K | – | 4304 |
|
|
2018
Q3 | $54K | Sell |
132
-6
| -4% | -$2.78K | ﹤0.01% | 4107 |
|
|
2018
Q2 | $75K | Sell |
138
-8
| -5% | -$4.25K | ﹤0.01% | 4039 |
|
|
2018
Q1 | $67K | Sell |
146
-35
| -19% | -$19.1K | ﹤0.01% | 4127 |
|
|
2017
Q4 | $121K | Buy |
181
+32
| +21% | +$19.3K | ﹤0.01% | 4049 |
|
|
2017
Q3 | $94K | Hold |
149
| – | – | ﹤0.01% | 4018 |
|
|
2017
Q2 | $72K | Buy |
+149
| New | +$90.9K | ﹤0.01% | 4083 |
|
|
2017
Q1 | – | Sell |
-65
| Closed | -$64K | – | 4339 |
|
|
2016
Q4 | $64K | Buy |
+65
| New | +$74.3K | ﹤0.01% | 4098 |
|
Other funds holding TCON
Bank of New York Mellon's TCON Position: Q2 2024 in Review
Bank of New York Mellon sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q2 2024, closing a stake of 513 shares — an estimated $4.41K sold.
Bank of New York Mellon first reported a position in TCON in Q4 2016 and held it in 21 quarters. The position peaked at $730K in Q4 2020. 1 fund tracked by Wall St. Rank holds TCON as of Q2 2024.
- Bank of New York Mellon reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Bank of New York Mellon sold 513 TRACON Pharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $4.41K.
- Bank of New York Mellon first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 21 quarters.
- Bank of New York Mellon's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $730K in Q4 2020.
- 1 fund tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Bank of New York Mellon's 13F filing for Q2 2024, filed 25 Jul 2024.